The Brain Bank was established in 1989 with the aim of providing high quality, clinically and neuropathologically well-characterised human brain and spinal cord tissue to the neuroscience community. The Brain Bank is partially funded by the Medical Research Council (MRC) and is part of the Basic and Clinical Neuroscience department at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) and the Department of Clinical Neuropathology at King’s College Hospital.
[1-65] Publications acknowledging LND Brain Bank 2016-2019
1. Aman, Y., et al., Reduced thermal sensitivity and increased opioidergic tone in the TASTPM mouse model of Alzheimer's disease. Pain, 2016. 157(10): p. 2285-96.
2. Baek, J.H., et al., Unfolded protein response is activated in Lewy body dementias. Neuropathol Appl Neurobiol, 2016. 42(4): p. 352-65.
3. Bereczki, E., et al., Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. Alzheimers Dement, 2016. 12(11): p. 1149-1158.
4. Bondulich, M.K., et al., Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate. Brain, 2016. 139(Pt 8): p. 2290-306.
5. Bukar Maina, M., Y.K. Al-Hilaly, and L.C. Serpell, Nuclear Tau and Its Potential Role in Alzheimer's Disease. Biomolecules, 2016. 6(1): p. 9.
6. Davidson, Y., et al., Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathol Appl Neurobiol, 2016. 42(3): p. 242-54.
7. Duarte, R.R., et al., Genome-wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cis-regulation of BORCS7, AS3MT, and NT5C2 in the human brain. Am J Med Genet B Neuropsychiatr Genet, 2016. 171(6): p. 806-14.
8. Gami-Patel, P., et al., The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions. Neurobiol Aging, 2016. 46: p. 192-203.
9. Guerreiro, R., et al., Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol Aging, 2016. 38: p. 214 e7-10.
10. Hannon, E., et al., Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci. Nat Neurosci, 2016. 19(1): p. 48-54.
11. Kenna, K.P., et al., NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet, 2016. 48(9): p. 1037-42.
12. Koss, D.J., et al., Soluble pre-fibrillar tau and beta-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Acta Neuropathol, 2016. 132(6): p. 875-895.
13. Kovacs, G.G., et al., Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol, 2016. 131(1): p. 87-102.
14. Kun-Rodrigues, C., et al., Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiol Aging, 2016.
15. Kurbatskaya, K., et al., Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. Acta Neuropathol Commun, 2016. 4: p. 34.
16. Lau, D.H., et al., Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease. Acta Neuropathol Commun, 2016. 4(1): p. 49.
17. Ling, H., et al., Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016. 139(Pt 12): p. 3237-3252.
18. Lunnon, K., et al., Variation in 5-hydroxymethylcytosine across human cortex and cerebellum. Genome Biol, 2016. 17: p. 27.
19. Marzi, S.J., et al., Tissue-specific patterns of allelically-skewed DNA methylation. Epigenetics, 2016. 11(1): p. 24-35.
20. Mirza, A., et al., The Identification of Aluminum in Human Brain Tissue Using Lumogallion and Fluorescence Microscopy. J Alzheimers Dis, 2016. 54(4): p. 1333-1338.
21. Niblock, M., et al., Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease. Neurobiol Aging, 2016. 37: p. 45-6.
22. Niblock, M., et al., Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathol Commun, 2016. 4: p. 18.
23. Robinson, A.C., et al., Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK. Acta Neuropathol, 2016. 132(5): p. 753-755.
24. Salta, E., et al., miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain. EMBO Mol Med, 2016. 8(9): p. 1005-18.
25. Sassi, C., et al., ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiol Aging, 2016. 46: p. 235 e1-9.
26. Sassi, C., et al., Influence of Coding Variability in APP-Abeta Metabolism Genes in Sporadic Alzheimer's Disease. PLoS One, 2016. 11(6): p. e0150079.
27. Smethurst, P., et al., In vitro prion-like behaviour of TDP-43 in ALS. Neurobiol Dis, 2016. 96: p. 236-247.
28. Tiwari, S.S., et al., Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain, 2016. 139(Pt 10): p. 2751-2765.
29. Troakes, C., et al., Clusterin expression is upregulated following acute head injury and localizes to astrocytes in old head injury. Neuropathology, 2016.
30. Vidal, B., et al., Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals. Neuropharmacology, 2016. 109: p. 88-95.
31. Alghamdi, A., et al., Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. J Alzheimers Dis, 2017. 57(2): p. 373-386.
32. Chong, J.R., et al., Increased Transforming Growth Factor beta2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Abeta42 Load. J Alzheimers Dis, 2017. 56(1): p. 157-166.
33. Ditsworth, D., et al., Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol, 2017. 133(6): p. 907-922.
34. Farg, M.A., et al., The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in Amyotrophic Lateral Sclerosis. Hum Mol Genet, 2017.
35. Hoglinger, G.U., et al., Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord, 2017. 32(6): p. 853-864.
36. Keogh, M.J., et al., Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Res, 2017. 27(1): p. 165-173.
37. King, A., et al., Unusual neuropathological features and increased brain aluminium in a resident of Camelford, UK. Neuropathol Appl Neurobiol, 2017. 43(6): p. 537-541.
38. Koss, D.J. and B. Platt, Alzheimer's disease pathology and the unfolded protein response: prospective pathways and therapeutic targets. Behav Pharmacol, 2017. 28(2 and 3 - Special Issue): p. 161-178.
39. Kun-Rodrigues, C., et al., Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiol Aging, 2017. 49: p. 214 e13-214 e15.
40. Lee, Y.B., et al., C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. Hum Mol Genet, 2017. 26(24): p. 4765-4777.
41. Mirza, A., et al., Aluminium in brain tissue in familial Alzheimer's disease. J Trace Elem Med Biol, 2017. 40: p. 30-36.
42. Moncini, S., et al., The miR-15/107 Family of microRNA Genes Regulates CDK5R1/p35 with Implications for Alzheimer's Disease Pathogenesis. Mol Neurobiol, 2017. 54(6): p. 4329-4342.
43. Respondek, G., et al., Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord, 2017. 32(7): p. 995-1005.
44. Sinclair, L.I. and S. Love, Effect of APOE Genotype on Synaptic Proteins in Earlier Adult Life. J Alzheimers Dis, 2017. 59(3): p. 1123-1137.
45. Smith, B.N., et al., Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med, 2017. 9(388).
46. Sproviero, W., et al., ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging, 2017. 51: p. 178 e1-178 e9.
47. Trist, B.G., et al., Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson's disease brain. Acta Neuropathol, 2017. 134(1): p. 113-127.
48. Troakes, C., et al., Clusterin expression is upregulated following acute head injury and localizes to astrocytes in old head injury. Neuropathology, 2017. 37(1): p. 12-24.
49. Viana, J., et al., Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions. Hum Mol Genet, 2017. 26(1): p. 210-225.
50. Wei, W., et al., Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathol Commun, 2017. 5(1): p. 13.
51. Guerreiro, R., et al., Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol, 2018. 17(1): p. 64-74.
52. Keogh, M.J., et al., Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. J Neurol Neurosurg Psychiatry, 2018. 89(8): p. 813-816.
53. Kun-Rodrigues, C., et al., A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiol Aging, 2018.
54. Marzi, S.J., et al., A histone acetylome-wide association study of Alzheimer's disease identifies disease-associated H3K27ac differences in the entorhinal cortex. Nat Neurosci, 2018. 21(11): p. 1618-1627.
55. Murray, C.E., et al., APOE epsilon4 is also required in TREM2 R47H variant carriers for Alzheimer's disease to develop. Neuropathol Appl Neurobiol, 2018.
56. Navarrete, F., et al., Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease. Neurotherapeutics, 2018. 15(2): p. 459-469.
57. Nicolas, A., et al., Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018. 97(6): p. 1268-1283 e6.
58. Pottier, C., et al., Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol, 2018. 17(6): p. 548-558.
59. Sassi, C., et al., Mendelian adult-onset leukodystrophy genes in Alzheimer's disease: critical influence of CSF1R and NOTCH3. Neurobiol Aging, 2018. 66: p. 179 e17-179 e29.
60. Smith, R.G., et al., Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. Alzheimers Dement, 2018. 14(12): p. 1580-1588.
61. Solomon, D.A., et al., A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-alpha mediates C9orf72-related neurodegeneration. Brain, 2018. 141(10): p. 2908-2924.
62. Wei, W., et al., Frequency and signature of somatic variants in 1461 human brain exomes. Genet Med, 2018.
63. Ashton, N.J., et al., Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun, 2019. 7(1): p. 5.
64. Gkazi, S.A., et al., Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. Neurobiol Aging, 2019. 73: p. 229 e5-229 e9.
65. Smith, A.R., et al., A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases. Neurobiol Aging, 2019. 74: p. 70-76.